Mineralys Therapeutics, a Radnor, Pennsylvania-based biopharmaceutical company developing medicines for hypertension and aldosterone-related comorbidities, has appointed Kristine Peterson and Lonnel Coats to its Board of Directors, as announced October 19, 2026. Both bring more than three decades of experience building commercial organizations and launching new therapies, including in cardiovascular and metabolic disease. They join ahead of the FDA’s December 22 target action date for lorundrostat, the company’s lead candidate for uncontrolled or resistant hypertension.
Jon Congleton, Chief Executive Officer of Mineralys, said the company is “delighted to welcome Kris and Lonnel” as it prepares for lorundrostat’s potential approval and launch. He noted that their commercial execution, operational leadership and public company board experience will be valuable as Mineralys becomes a commercial-stage organization.
Peterson said she’s honored to join at such a pivotal time. Having spent much of her career launching new medicines, including in cardiovascular disease, she appreciates the unmet need among patients whose hypertension isn’t controlled by current therapies. Coats said too many patients still can’t reach their blood pressure goals with today’s treatments, and that lorundrostat has significant potential to offer a targeted approach for hypertension driven by dysregulated aldosterone.
About Kristine Peterson
Peterson most recently served as Chief Executive Officer of Valeritas, a commercial-stage medical technology company, from 2009 to 2016. Before that, she was Company Group Chair of the Biotechnology Group and Executive Vice President of Pharmaceutical Group Strategic Marketing at Johnson & Johnson, where she led commercial, R&D and biologics manufacturing in oncology, immunology and cell therapy. She previously served as Senior Vice President, Commercial Operations, of Biovail Corporation and President of Biovail Pharmaceuticals. She began her career with 20 years at Bristol-Myers Squibb in senior sales, marketing and general management roles, including leading its cardiovascular and metabolic disease business unit.
Peterson currently serves on the boards of ArriVent BioPharma, Enanta Pharmaceuticals and Immunocore. She previously served on the boards of the Biotechnology Innovation Organization (BIO), ImmunoGen, Amarin, Paratek Pharmaceuticals, EyePoint Pharmaceuticals and AFYX Therapeutics. She holds a B.S. in Marketing and an MBA from the University of Illinois.
About Lonnel Coats
Coats most recently served as Chief Executive Officer and a director of Lexicon Pharmaceuticals from 2014 to 2024. Before Lexicon, he spent a decade in leadership roles at Eisai, first as President and Chief Operating Officer and then as Chief Executive Officer of North America. At Eisai, he oversaw commercialization across oncology, neurology, gastrointestinal disorders, epilepsy and metabolic disorders. Earlier, he spent eight years in management and sales roles at Janssen Pharmaceuticals, a division of Johnson & Johnson.
Coats currently serves on the board of Relay Therapeutics. He holds a B.S. in Public Administration from Oakland University.
About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific.
